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Influenza A virus (IAV) is a significant human pathogen causing annual epidemics and 
occasional pandemics. The virus evolves rapidly avoiding vaccine-induced immunity and 
virus-targeted therapeutics. Development of novel options for the control of influenza 
requires detailed understanding of virus-host interactions.  
The viral non-structural protein NS1 is a key regulator of IAV-host cell interactions. In this 
thesis we studied the role of NS1 C-terminus in modulation of cellular responses to IAV 
infection. 
In our study gene expression and phosphokinase profiling were analyzed in human 
macrophages infected with a wild type IAV or with three mutant IAVs expressing 
differently C-terminally truncated NS1 proteins. 
The current study revealed that one of the truncations in the NS1 C-terminus resulted in 
an improved ability of the virus to inhibit transcriptional activation of antiviral genes in the 
infected cells. Moreover, it resulted in the activation of five cellular phosphoproteins 
suggesting a possible involvement of the NS1 C-terminus in regulation of signal 
transduction pathways in the infected cells. Based on these observations, we suggest that 
NS1 amino acids 202-210 possess some features that may contribute to the ability of IAV 
to counteract host viral responses. This amino acid stretch should be studied further. 
Understanding host responses and their underlying mechanisms could facilitate discovery 
of better options to control IAV, to mitigate annual epidemics and to prevent future 
influenza pandemics. 
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Influenssa A -virus on merkittävä ihmispatogeeni, joka aiheuttaa vuosittain epidemioita ja 
toisinaan pandemioita. Virus muuntautuu nopeasti harhauttaen rokotteella hankitun 
immuniteetin ja virusinfektion hoitoon kehitetyt menetelmät. Uusien influenssan 
torjuntakeinojen kehittäminen edellyttää viruksen ja sen isännän välisten vuorovaikutusten 
syvällistä ymmärtämistä.   
Viruksen ei-rakenneproteiini NS1 on keskeinen influenssa A -viruksen ja isäntäsolun 
vuorovaikutuksen säätelijä. Tässä opinnäytetyössä tutkittiin NS1:n C-terminuksen 
merkitystä influenssa A -virusinfektion aikaansaaman soluvasteen muuntamisessa. 
Tutkimuksessa geenien ilmentymistä ja fosfokinaaseja analysoitiin ihmisen makrofageissa. 
Makrofagit infektoitiin luonnonkantaisella influenssa A -viruksella tai jollakin kolmesta 
mutatoidusta influenssa A -viruksesta, joiden NS1-proteiinin C-terminusta oli lyhennetty eri 
tavoin. 
Tutkimus osoitti, että yksi NS1-proteiinin lyhennetty C-terminus edesauttoi viruksen kykyä 
estää infektoitujen solujen virusvastetta ilmentävien geenien transkriptioaktiivisuus. Se 
aktivoi myös solun viittä fosfoproteiinia, mikä viittaa NS1:n C-terminuksen mahdolliseen 
osallisuuteen infektoituneiden solujen signaalitransduktioreittien säätelyssä. Näihin 
havaintoihin perustuen on syytä olettaa, että NS1:n aminohapoilla 202 - 210 on 
ominaisuuksia, jotka saattavat parantaa influenssa A -viruksen kykyä torjua isännän 
virusvastetta. Kyseessä olevaa aminohappojaksoa olisi hyvä tutkia jatkossa lisää. 
Isännän vasteiden ja niihin sisältyvien mekanismien ymmärtäminen saattaa auttaa 
löytämään parempia keinoja torjua influenssa A -viruksia, lieventää kausiepidemioita ja 
estää tulevia influenssapandemioita.  
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1 Introduction 
 
Influenza A virus (IAV) is a respiratory virus and an important globally circulating 
human pathogen that causes annual epidemics (up to 5 million cases of severe illness 
and 250 000 - 500 000 deaths) and occasional pandemics. It represents a constant 
health threat and causes significant economic burden. [1, 2.]  
 
Pandemic influenza viruses cause significant mortality in humans. According to 
research the following three essential prerequisites are needed for a pandemic to 
occur: transmission of a novel viral subtype to humans, viral replication causing 
disease in humans and efficient human-to-human transmission of the virus. [3.] In the 
course of the last 400 years at least 31 pandemics have been registered and during the 
last one hundred years, 4 influenza viruses have caused major pandemics (Figure 1): 
the 1918 H1N1 virus (Spanish flu), the 1957 H2N2 virus (Asian influenza), the 1968 
H3N2 virus (Hong Kong influenza) and the 2009 H1N1 virus (Swine flu). [4, 5.]  
 
 
 
Figure 1. Recorded human influenza virus pandemics since 1885 (early subtypes 
inferred) [5]  
 
The Spanish flu raged in 1918-1919 causing death of at least 50 million people mostly 
due to secondary bacterial pneumonias. It was most likely caused by the transmission 
of an avian influenza virus to humans. [3.] The global mortality caused by Asian 
influenza in 1957 was estimated to be 1-2 million deaths [6.] and the Hong Kong 
influenza resulted in 1-4 million deaths [7].   According to the World Health 
2 
 
Organization (WHO) 48 countries have reported severe illness and death cases of the 
most recent IAV pandemic (swine flu, H1N1/2009). This pandemic caused over 
200 000 deaths. [8, 9.]    
 
Recently in 2013, there have been more and more cases of influenza A (H7N9) virus 
registered in humans in China. This virus is one subtype among the larger group of H7 
viruses, which normally circulate among birds. Even though there is so far no indication 
that this virus can be transmitted between people the disease is of great concern since 
most patients have been severely ill. [10.] Currently no vaccine is available for this 
influenza virus subtype [11].  
 
These facts alone give us a compelling reason to study influenza A virus (IAV) further. 
 
 
 
I had a little bird 
And it´s name was Enza, 
I opened the window, 
And in-flew-Enza. 
 
A skipping rope rhyme from 1919 [1] 
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2 Review of literature 
2.1 Influenza A virus 
Influenza A viruses belong to the family Orthomyxoviridae (name derives from their 
ability to bind sialic acid in mucoproteins). They are enveloped and usually rounded as 
can be seen in Figure 2 but can also be filamentous. The virions are 80-120 nm in 
diameter. The influenza A viruses are classified into subtypes depending upon their 
surface glycoproteins, haemagglutinin (HA) and neuraminidase (NA). Up to this date 
18 different HA (H1 to H18) and 11 NA subtypes (N1 to N11) have been identified. [12, 
13, 14, 15.]  Any HA or NA antigenic subtype pose a potential threat to public health. 
In humans antigenic subtypes H1, H2, H3 and N1, N2, N8, N9 have so far been 
detected. [10,16.] 
 
                       
Figure 2. Influenza A virion [17]  
  
IAV has a segmented ssRNA(-) linear genome encapsidated by nucleoprotein (NP) 
(Figure 2). The IAV genome contains 8 segments (Figure 3) which encode 12-14 
proteins depending on strains. Segments size ranges from 890 to 2 341 nt, and the 
total size of the genome is 13,5 Kb. [12.]  
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Figure 3. The genome of influenza A virus [12]    
 
The IAV genome encodes for viral proteins as shown in Table 1: polymerase basic 
protein 2 (PB2), polymerase basic proteins 1-F1 (PB1-F1) and 1-F2 (PB1-F2), 
polymerase acidic proteins (PA and PA-X), hemagglutinin (HA), nucleoprotein (NP), 
neuraminidase (NA), matrix 1 (M1), matrix 2 (M2), non-structural protein 1 (NS1) and 
non-structural protein 2 (NS2). [18.] Such novel influenza proteins as PA-N155 and PA-
N182 have been identified in recent studies. According to them these proteins 
participate in replication processes. [19.]  
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Table 1. Influenza A virus gene segments and encoded proteins [20]  
        
 Influenza A virus gene segments and encoded proteins 
        
RNA segment Nucleotides Protein Amino acids 
1 2341 PB2 759 
2 2341 PB1 757 
    PB1-F2 87-90 
3 2230 PA 716 
    PA-X 252 
4 1778 HA 566 
5 1565 NA 498 
6 1413 NP 454 
7 1027 M1 252 
    M2 97 
8 875 NS1 230 
    NS2 (NEP) 121 
 
Viral ribonucleoproteins (vRNP) are comprised of 6 proteins - the NP which forms viral 
capsids and regulates RNA synthesis and the five polymerase subunits i.e. proteins  
PB2 (regulation of transcription), PB1 (polymerase activity, cleavage of pre-mRNAs), 
PB1-F2 (enhancement of immune cell apoptosis), PA (regulation of transcription and 
replication) and PA-X (modulation of host antiviral response). They transcribe one 
mRNA from each genomic RNA segment forming ribonucleoprotein (RNP) complexes. 
[20.] 
 
Hemagglutinin (HA) is a surface antigen responsible for binding the virus to the cell 
that is being infected (sialic acid-receptor binding) and subsequently for the 
penetration of viral RNA genome into the cell. The HA protein is a major antigenic 
determinant and induces a strong immune response. Approximately 25 % of viral 
proteins consist of HA. [20.] 
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The neuraminidase (NA) represents about 5% of viral proteins and it  is the second 
major surface antigen playing a decisive role in late stage of infection. The NA protein 
removes sialic acid from sialyloligosaccharides and releases newly assembled virions 
from the cell surface. It also prevents the self-aggregation of virus particles. [20.] 
 
The M1 matrix protein is the major structural component inside the virion and forms a 
shell around the vRNPs. The M1 protein is also considered to play a significant role 
during the replication and assembly of the virus and initiate the budding of the virus. 
[20.] The matrix protein M2 forms a proton-specific transmembrane (TM) ion channel, 
and it becomes active at an acidic pH. This protein plays an important role in both 
early and late stages of virus infection. In the beginning of infection the M2 ion 
channel functions between the steps of virus penetration and uncoating. [20.] 
 
Non-structural proteins (NS1 and NS2) are encoded by the eighth gene segment of IAV 
genome. The NS1 is regarded to be responsible for optimal replication of the virus in 
the host cell. Importantly, the NS1 protein is assumed to play a crucial role in 
suppressing the host cell antiviral responses and inhibiting apoptosis by multiple 
mechanisms.  The NS1 can also inhibit the nuclear export of host mRNA and the 
splicing of pre-mRNA. The NS2 is nowadays referred to as a nuclear export protein 
(NEP). It mediates the export of progeny vRNPs by acting as an adapter between the 
nuclear export machinery and the M1-vRNP complex. [21.]  
 
An overview of the non-structural protein 1 (NS1) and the non-structural protein 2 
(NS2) is presented in Figure 4. A more specific representation of the NS1 protein will 
follow later in this study. 
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Figure 4. Influenza A virus (A/WS/1933(H1N1)) sequences of non-structural protein 1 
(NS1) and non-structural protein 2 (NS2) [22]   
2.1.1 Antigenic variation 
All the pandemics mentioned earlier in this study began as a result of the introduction 
and successful adaptation of a novel hemagglutinin subtype to humans from an animal 
source, meaning that an antigenic shift took place.  In 1918 all eight genetic segments 
are thought to have originated from avian influenza virus (Figure 5). In 1957, three 
new genetic segments from avian influenza virus were introduced (HA, NA, PB1). This 
subtype H2N2 virus had five segments from the 1918 virus. In 1968, two new genetic 
segments from H3 avian influenza virus were introduced (HA, PB1). Subtype H3N2 
virus had the remaining segments from the H2N2 virus.  
 
 
1918 Spanish flu       1957 Asian flu  1968 Hong Kong flu  2009 Swine flu 
A/H1N1 virus        A/H2N2 virus  A/H3N2 virus   A/H1N1 virus   
 
Figure 5.  Reassortment of the influenza A virus genome [24, 25] 
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The strain of 2009 pandemic influenza virus is a reassortant of avian, human, and 
swine influenza viruses (subtype H1N1). [23.] This process is illustrated in the figure 
on the previous page (Figure 5), which shows how a cell that is co-infected with 
different influenza viruses. The infected cell produces both parental viruses as well as 
reassortant ones which inherit some RNA segments from one strain and the remaining 
ones from the other strain. 
Usually the RNA virus diversity is achieved by mutation. Influenza virus with a 
segmented genome, however, generates diversity through reassortment.  In case of a 
cell being infected with two different influenza viruses the RNAs of both viruses are 
copied in the nucleus. When new virus particles are assembled at the plasma 
membrane, each of the 8 RNA segments may originate from either infecting virus. The 
progeny that inherits RNAs from both parents is called a reassortant. [23.] 
 
The epidemiological behaviour of influenza virus in human population relates to the 
two types of antigenic variation of its envelope glycoproteins (HA and NA), i.e. 
antigenic drift and antigenic shift. Antigenic drift involves a minor change (point 
mutations) in the surface H-antigens resulting from an immune selective pressure. The 
antigenic shift means a complete change in H-antigen resulting from a replacement of 
the genomic RNA segment encoding surface antigens and leading to appearance of a 
novel potentially pandemic IAV. The new virus would be antigenically different from 
earlier viruses and would not have been able to evolve from them by mutation. Drifted 
viruses are less virulent than shifted ones. [26, 27.] These antigenic variations are 
shown in Figure 6. 
 
 
Figure 6. The two types of antigenic variation [27] 
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2.1.2 Life cycle of influenza A virus 
There are three essential phases of replication for IAV as well as for all types of viruses 
– namely the initiation of infection, the replication and expression of the virus genome 
and the release of mature virions from the infected cell [28]. Unlike most RNA viruses, 
Orthomyxoviruses replicate in the cell nucleus. The influenza viral life cycle is 
presented in Figure 7.  
 
                
Figure 7.  Schematic diagram of the influenza viral life cycle [25.] 
 
It is typical for viruses that they are able to infect only a limited number of hosts 
(known as host range).  The most common explanation for this is the "lock and key" 
mechanism meaning that a certain proteins on the virus particle must fit certain 
receptor sites on the particular host's cell surface. [29.] 
 
The AIV binds to sialic acid-containing receptors on the surface of the host cell through 
HA protein and after endocytosis, fusion of virus membrane with the vesicle membrane 
and uncoating the viral genome (viral ribonucleoproteins; vRNPs) is released into the 
cytoplasm. Then, the vRNPs are transported to the nucleus for transcription. Viral RNA-
dependent RNA polymerase (RdRp) transcribes all the genomic genes to produce 
mRNAs (Figure 8) and express viral proteins. Viral genomes are transcribed using 
fragments of the cellular mRNA as primers for mRNA synthesis initiation. The IAV is 
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able to efficiently shut off the host cell protein synthesis and selectively translate viral 
RNA. The virus "de-caps" host mRNA, making them susceptible to degradation. 
 
 
Figure 8. Negative stranded RNA virus transcription [12]  
 
Six out of eight positive-sense viral messenger RNAs (mRNAs) are immediately 
exported out of the nucleus into the cytoplasm for protein synthesis (translation) by 
cellular ribosomes. Two mRNAs encoding non-structural and matrix proteins are further 
processed. The IAV exploits cellular translation for efficient production of its own 
protein components and enzymes. [29.] 
The encapsidated vRNPs are then transported into the nucleus where viral genome 
replicates using the host's cellular machinery. The non-structural protein NS1 of IAV 
sets up multiple cellular pathways to facilitate virus replication. Viral RdRp performs 
genomic (-) RNA replication through antigenomic (+) RNA intermediate as presented in 
Figure 9. [25, 28, 30.]   
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Figure 9. Negative stranded RNA virus replication [12]  
 
Early viral proteins required for viral RNA replication and vRNP assembly (which also 
occur in the nucleus) are imported back into the nucleus. Late in the infection cycle, 
the newly synthesized vRNPs form and leave the nucleus with the assistance of M1 and 
NS2 (NEP) proteins. Finally, progeny virions assemble and bud at the plasma 
membrane. [25, 28, 30.]   
2.2 Non-structural protein NS1  
The viral non-structural protein NS1 is a phosphoprotein with a relatively low molecular 
mass (approx. 26 kDa). The NS1 is encoded by all strains of influenza A virus. It is a 
key regulator of virus-host interactions. It interacts with nucleic acids and multiple host 
proteins to limit cellular antiviral responses and thus secure effective replication of the 
virus. The length of NS1 proteins of human and avian IAV strains varies from 215 to 
237 amino acids. The strains can differ in their primary sequences by more than 30%. 
This indicates specific adaptations to the respective host environment. [13, 31.] In this 
chapter the structure of the NS1 protein of influenza A virus is represented and the 
functions of this protein in virus-host interaction processes are reviewed.  
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2.2.1 Role of NS1 in molecular virus-host interactions  
The viral NS1 has a crucial role in counteracting host cell responses in multiple ways in 
order to secure the production of viral particles. The NS1 protein has two major 
functional domains – N-terminus domain (amino acids 1 to 73) and C-terminus domain 
(amino acids 74 to 230) - with the help of which it may impact virulence by binding to 
cellular signalling proteins and interfering with the effects of several antiviral host 
factors. The NS1 C-terminus regulates host immune responses aiming at weakening 
innate and adaptive immunity by inhibiting host signal transduction and antiviral gene 
expression. [32.]  
 
Innate immune responses are stimulated after the recognition of a pathogen by a 
pathogen-recognition receptor. The host innate interferon (IFN) response is a potent 
antiviral mechanism by which the host is able to limit virus replication and spread. Both 
RNA and DNA viruses induce IFNs by producing viral double-stranded RNA (dsRNA). 
The dsRNA-binding domain of NS1 interferes with host pathways during influenza 
infections. The infections lead to the activation of RIG-I (retinoic acid-inducible gene I). 
Type I interferons (such as IFN-α or IFN-β) are soluble cytokines that cells synthesize 
and secrete in response to virus infection and they are induced through the RIG-I 
pathway. The NS1 protein inhibits RIG-I-mediated innate immune responses by 
targeting RIG-I and blocking its signalling. In addition, NS1 targets TRIM25 (tripartite 
motif-containing protein 25) and interferes with caspase-1 (apoptosis-related cysteine 
peptidase) activation. The levels of IFNα/β mRNA are also reduced by NS1 interfering 
with mRNA splicing, the polyadenylation and nuclear export of cellular pre-mRNAs.  
[13, 25, 33, 34.]  
 
The C-terminus domain interacts with cleavage and polyadenylation specificity factor 
(CPSF) and poly(A)-binding protein II (PABII) which are responsible for efficient 3’ end 
cleavage and polyadenylation of cellular pre-mRNAs in the nucleus. This NS1 function 
blocks cellular mRNA processing in IAV-infected cells yet not harming the synthesis of 
viral mRNA since its polyadenylation is run by a different mechanism.  
 
NS1 suppresses the activity and function of the dsRNA-dependent PKR (cellular protein 
kinase R) which is encoded by IFN-stimulated genes (ISGs) by preventing it from 
phosphorylating eukaryotic translation elongation factor eIF-2α and allowing viral 
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protein synthesis to continue. NS1 binds to double-stranded RNA (dsRNA) to prevent 
the dsRNA-dependent activation of interferon-induced 2'-5'-oligoadenylate synthetase 
(OAS), and the subsequent activation of Ribonuclease L (RNasel) which is responsible 
for degradation of viral RNA. These cytoplasmic antiviral proteins – OAS, RNase L and 
PKR - are central regulators of viral transcription and translation processes, other 
innate defences and the host apoptosis. [13, 25, 32, 34.] 
 
The Akt (also known as protein kinase B, PKB) and PI3K (phosphoinositide 3-kinase) 
play a significant role in several host cell processes, including the suppression of host 
apoptotic response, cell growth, transcription, proliferation and cytokine production. 
NS1 stimulates the PI3K/Akt pathway which is critical for efficient IAV replication, 
presumably by preventing premature apoptosis. The activation of this pathway occurs 
in the first 8 h of infection and is caused by expression of the viral NS1 protein. [13, 
34.] 
 
It has appeared that the C-terminus four amino acids of avian influenza virus NS1 
proteins comprise the consensus sequence of a PDZ domain ligand (PL). PDZ domains 
are protein–protein recognition modules participating in organizing diverse cell-
signalling assemblies. These domains have an effect on virulence, most probably 
through interaction with the cellular PDZ domain proteins SCRIB  (scribble homolog), 
Dlg1 (disks large homolog 1), and membrane-associated guanylate kinase MAGI-1, -2, 
and -3, which regulate apoptosis. [13, 34.] 
 
The nucleo-cytoplasmic trafficking of RNA and proteins is critical for correct cellular 
functions and survival. A well-known nuclear function of the IAV NS1 protein is the 
inhibition of the splicing and nucleo-cytoplasmic export of cellular mRNAs. In the later 
stage of the infection, the NS1 is present in the cytoplasm and binds to the 5'-
untranslated region (5' UTR) of some viral mRNAs in order to stimulate their 
translation.  [31, 35.] 
 
14 
 
2.2.2 Structure of NS1  
Schematic representation of a 230 amino acid long NS1 protein is presented in yellow 
in Figure 10. The N-terminus forms a functional RNA-binding domain, while the C-
terminus (effector domain) binds to distinct cellular proteins and affects their function 
thus predominantly mediating interactions with host-cell proteins. The last 20 amino 
acids of the C-terminus may be natively unstructured.  NS1 contains two nuclear 
localization sequences (NLS1 and NLS2), and a nuclear export sequence (NES). A 
nucleolar localization sequence (NoLS) has been found in some strains and it is related 
to NLS2. NS1 interacts with nucleic acids and multiple cellular factors during infection. 
A number of binding sites for NS1 partners have already been identified in NS1. [13.] 
 
 
Figure 10. The structure of NS1 protein [13] 
 
Residues Arg-38 [R38] and Lys-41 [K41] which are involved in RNA-binding are 
implicated in the inhibition of OAS/RNase L, Jun N-terminal kinase, and RIG-I. The NS1 
protein contains also binding sites for poly(A)-binding protein I (PABPI), p85β, 
importin-α, nucleolin, NS1-BP, eIF4GI, hStaufen, NS1-I, PKR, PACT, CPSF30, poly(A)-
15 
 
binding protein II (PABPII), Crk/CrkL, PDZ domain containing proteins, the viral 
polymerase, and components of the cellular mRNA nuclear export machinery (E1B-AP5, 
p15, NXF1, and Rae1). [13.] 
 
The amino acids of wild type influenza A virus (strain A/Wilson-Smith/1933 H1N1) NS1 
protein (total 230 a. a.) are presented in Figure 11 below.   
 
        10         20         30         40         50         60  
MDPNTVSSFQ VDCFLWHVRK RVADQELGDA PFLDRLRRDQ KSLRGRGSTL GLDIETATRA  
 
        70         80         90        100        110        120  
GKQIVERILK EESDEALKMT MASVPASRYL TDMTLEEMSR HWFMLMPKQK VAGPLCIRMD  
 
       130        140        150        160        170        180  
QAIMDKNIIL KANFSVILDR LETLILLRAF TEEGTIVGEI SPLPSLPGHT DEDVKNAVGV  
 
       19        20        21        22        23
LIGGLEWNNN TVRVSETLQR FAWRSSNENG RPPLTPKQKR KMAGTIRSEV  
0 0 0 0 0  
 
 
Figure 11. Non-structural protein 1, influenza A virus, amino acids [36] 
 
 
The development of novel options for the control of influenza requires identification of 
virulence determinants and detailed understanding of virus-host interactions. Naturally 
occurring viruses may differ from each other by a number of determinants, including 
the length of the NS1 protein. In previous studies clinical isolates of IAV containing C-
terminus truncations of NS1 were found. The truncated region contains motifs which 
may be important for modulation of antiviral responses and infection progression.  
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3 Aim of the study 
 
Exploring the mechanism of regulation of host responses is crucial for understanding 
the pathogenesis of IAV. The principal question which is addressed in this thesis is the 
role that the NS1 protein C-terminus presumably has in regulating virus-host 
interactions and counteracting cellular antiviral responses at transcriptional and post-
transcriptional level. To understand how this is operated by the above mentioned viral 
protein terminus a research project whose material and methods will be described in 
the following chapter was begun.  
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4 Materials and methods 
 
For this study mammalian cell lines and human primary cells were cultured. A wild-type 
influenza virus and mutant viruses made of it were also generated and propagated. 
The viruses were then sequenced and characterized. Finally gene expression and 
phosphokinase profiling were performed. These stages are shown in Figure 12 and 
described more in detail later in this chapter.  
 
 
 
Maintenance of mammalian cell cultures
 
 
Generation and propagation of viruses
 
Sequencing of viruses
 
 
Characterization of viruses 
        Virus growth curves 
 
 
Phosphokinase profiling  Gene expression profiling  
 
Figure 12. The stages of the study 
4.1 Cell Culture 
For this study the Vero and Madin-Darby canine kidney (MDCK) immortalized 
mammalian cell lines and primary human macrophages were used. The MDCK cells are 
kidney epithelial cells that were isolated from a dog in 1958 by S.H. Madin and N.B. 
Darby and have been widely used for influenza A virus studies for decades [37]. Vero 
cells are kidney epithelial cells isolated from African green monkey in the 1960s and 
are also widely used in virology with the advantage that these cells have abrogated 
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IFN alpha and IFN beta signalling allowing propagation of attenuated mutant viruses 
[38, 39]. To avoid possible effects of cell immortalization on IAV infection primary cells 
were used for critical experiments. Pneumocytes and alveolar macrophages express 
similar responses to IAV infection, hence human macrophages were chosen as primary 
cells to be used in this study. 
 
 
4.1.1 Vero and MDCK  
 
Vero and MDCK cells were cultured in Dulbecco's modified Eagle's minimal essential 
medium (DMEM) supplied with 200 mM 2-Amino-4-carbamoylbutanoic acid (L-
Glutamine, Lonza), 10% heat-inactivated fetal bovine serum (FBS, Gibco) and 50 U/ml 
penicillin-streptomycin mix (PenStrep, Lonza). Cells were cultured as a monolayer 
attached to the flask bottom in 37 °C in 5% CO2.  
Cells were regularly passaged for experimental needs and to prevent inhibitory over-
growth. For this, the cultured medium was removed from a confluent flask and cells 
were washed twice with phosphate buffered saline (PBS, 137 mM NaCl, 2,7 mM KCl, 8 
mM Na2HPO4, 1,46 mM KH2PO4, Sigma). To detach the cells, a monolayer was covered 
with Trypsin-EDTA solution (Lonza) pre-warmed to 37 °C. After a 5 minute incubation 
at 37 °C cells were detached from the flask bottom and growth medium was added to 
inactivate trypsin and to achieve desired dilution for passaging. A fraction of cell 
suspension was transferred in a new flask containing fresh medium and distributed 
evenly by tilting the flask several times. 
 
4.1.2 Macrophages 
 
During influenza viral replication in bronchial epithelial cells macrophages being one of 
the earliest targets to be infected are indispensable in alveolar host defense and 
controlling influenza virus in pulmonary organs. Macrophages were used in this study 
since it is presumed that pneumocytes and alveolar macrophages (lung macrophages) 
express similar genetic responses when IAV replicates in them. Scientifically, the 
macrophages may even be a better research object since they react in a “more 
professional” way. This is due to the fact that macrophages communicate with B- and 
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T-cells and the latters need information from macrophages to be able to induce an 
immune response.  
 
Macrophages were differentiated from peripheral blood mononuclear cells (PBMCs) 
extracted from blood donated by a healthy individual. PBMCs were separated by 
density gradient centrifugation of blood in Lymphocyte Separation Medium (LSM, D= 
1,077 g/ml, PAA Laboratories). Eight ml of heparinized blood was carefully pipetted on 
top of 7 ml of LSM of in 15 ml tubes and centrifuged at 1200 x g (without break) for 20 
minutes. After centrifugation the PBMCs were concentrated in the interphase between 
the plasma and separation solution and were collected with a sterile pipette (Figure 
13). 
 
                    
Figure 13. Extraction of PBMCs from blood  
 
 
Following collection, the PBMCs were washed with PBS (PBS 3 x volume) and 
centrifuged at 400x g for 15 minutes. The supernatant was discarded and the cell 
pellets were suspended in PBS for a second wash and centrifugation at 200x g for 10 
minutes. The supernatant was discarded again and the cell pellet was resuspended in 
1 ml of PBS. To determine number of cells for further cultivation, cells were counted 
using a haemocytometer. The PBMCs were suspended in RPMI 1640 (Roswell Park 
Memorial Institute - 1640, Lonza) supplied with 1 M pH 7,3  N-(2-
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Hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid) (HEPES, PAA Laboratories), 200 
mM L-Glutamine and 50 U/ml PenStrep and the desired amount of cells was seeded on 
a growth dish. Monocytes were let to attach to the dish bottom for a minimum of 1 
hour after which cells were washed twice with PBS to remove unattached cells. The 
monocytes were differentiated into macrophages in serum-free medium (SFM, 
GIBCO®) supplied with 20mM L-Glutamine, 50U/ml of PenStrep and 10 ng/ml of 
human granulocyte macrophage-colony stimulating factor (GM-CSF, Sigma-Aldrich) for 
7 days at 37°C and 5% CO2. The growth medium was changed to a fresh one every 
second day. During the differentiation into macrophages the monocytes changed their 
size and shape.  
4.2 Virus work 
In this study a wild type A/Wilson-Smith/1933 H1N1 IAV strain (wtWSN further in the 
text) and its mutants A/WSN/33-202 (WSN-202 further in the text), A/WSN/33-210 
(WSN-210 further in the text) and A/WSN/33-220 (WSN-220 further in the text) were 
used. The mutants were generated using reverse genetics system for A/WSN/33 IAV.  
Since a gene mutation can only be made by having a gene inserted into a plasmid and 
there is not yet any plasmid of influenza A/H1N1/pdm09 (swine flu) available, the 
different mutations were made of A/WSN/33 (Figure 14, on the next page). A WSN-
202 virus contains mutation W203Stop in NS1 protein (in the NS1 protein of WSN-202 
a tryptophan in 203 was changed to a Stop codon resulting in a 28-amino-acid C-
terminus truncation) and expresses NS1 with a C-terminus 28-amino-acid truncation. A 
WSN-210 virus contains mutation R211Stop in NS1 protein and expresses NS1 with a 
C-terminus 20-amino-acid truncation. A WSN-220 virus contains mutation K221Stop in 
NS1 protein and expresses NS1 with a C-terminus 10-amino-acid truncation.  
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Figure 14. NS1 (wtWSN and its mutant viruses) 
 
4.2.1 Virus infections 
 
For infection of MDCKs and Vero cells were washed two times with PBS and the virus 
was added in virus-growth medium (VGM; DMEM supplied with 20 mM L-Glutamine, 50 
U/ml PenStrep, 0.2% bovine serum albumin (BSA, Gibco) and 1 µg/µl N-p-Tosyl-L-
phenylalanine chloromethyl ketone treated trypsin (TPCK-trypsin, Sigma-Aldrich)). For 
infection of macrophages, medium was discarded and the virus was added in fresh 
SFM supplied with 20mM L-Glutamine and 50 U/ml PenStrep. Infected cells were 
incubated in 37 °C and 5% CO2. 
 
4.2.2 Propagation of viruses 
 
In this study wtWSN, WSN-202, WSN-210 and WSN-220 were propagated in Vero cells 
which are immunocompromised thus allowing replication of mutant and attenuated 
viruses. For virus propagation Vero cell monolayers in T175 flasks were washed twice 
with PBS. Next, 20 ml of VGM was added to the flasks. Following this, cells were 
infected with viruses at multiplicity of infection (MOI) 0,01. MOI was calculated as the 
ratio of infectious virus particles number to the number of cells to be infected. The 
infected cells were incubated until cytopathic effect (CPE; changes in cell morphology 
and cell death caused by infection and followed by detachment from the flask bottom) 
was observed. When CPE > 90% was achieved viruses were harvested as follows: 
VGM from infected cells was collected and at 1200x g for 10 min to pellet dead dells 
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and cell debris. After centrifugation the clarified supernatant was collected, aliquotted 
and stored at - 80 °C.  
 
4.2.3 Virus sequencing 
 
To ensure that propagated viruses did retain the generated mutations in the NS1 gene 
all virus stocks were sequenced prior to use. For sequencing total RNA was extracted 
from 500 µl of virus stocks using RNeasy Mini kit (Qiagen) according to manufacturer’s 
protocol.  
 
The extracted viral RNA was amplified for sequencing. The NS segment DNA was 
generated in a one-step RT-PCR using Invitrogen SuperScript™ One-Step RT-PCR 
system (Life Technologies), a common Uni12 oligo, 32, (5´-AGCAAAAGCAGG / 31,4 
µg/OD) for first-strand cDNA synthesis and specific WSN NS1 oligos (forward: 5’-
ATGGACCCAAACACTGTGTCAA / 30,7 µg/OD, reverse: 5’-TCAAACTTCTGACCTAATTG / 
32,3 µg/OD) for amplification. In one-step RT-PCR all reaction components were mixed 
in one tube prior to starting the reactions.  
 
Mixture (for one reaction): 
 
Rnase-free water  1,9 µl 
vRNA   10 µl 
Primers   0,05 µl (each)          
Buffer   12,5 µl 
Enzyme mix  0,5 µl 
 
This method offered simplicity and convenience and minimized the possibility for 
contamination. The reaction was set up as shown in Table 2 on the next page. 
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Table 2. One-step RT-PCR programme 
One-step RT-PCR   Temperature Time   
Reverse transcription   42°C  15 min   
    55°C  15 min   
    60°C  5 min   
Denaturation   94°C  2 min   
Primary amplification Denaturation 94°C  30 sec 5 cycles 
  Annealing 45°C  30 sec   
    45°C - 68°C 46 sec; 0,5°C/sec,    
      slow ramp   
  Extension 68°C  3 min   
Secondary amplification Denaturation 94°C  30 sec 30 cycles 
  Annealing 57°C  30 sec   
  Extension 68°C  3 min   
    68°C  5 min   
 
To ensure that the amplification had been successful the DNA products were separated 
by electrophoresis in a 1 % agarose gel in tris-acetate buffer (1XTAE, 40mM Tris, 
20mM acetic acid, and 1mM EDTA). For further visualization of DNA 10 mg/ml 
Ethidium Bromide (VWR International) was added to the gel. DNA was visualized in 
260 nm UV light. The DNA concentration was measured using Nanodrop 1000 
Spectrophotometer (Thermo Scientific). Prior to sequencing reaction the PCR mix was 
treated with exonuclease I (ExoI, Thermo Scientific) to degrade residual Uni12 
oligonucleotides and thermosensitive alkaline phosphatase (FastAP, ThermoScientific) 
to prevent incorporation of unlabelled dNTPs during sequencing reaction. For this 10 
units of ExoI and 1 unit of FastAP were added to 5 µl of PCR mix. The reaction was 
incubated at 37 °C for 30 minutes after which the enzymes were inactivated by 
incubation at 90 °C for 10 minutes. Sequencing was done by the Sanger method in a 
local sequencing facility using a NS1 specific primer 5’-TTCACCACTGCCCTCTCTTC. 
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4.2.4 Plaque assay 
 
Determining virus titre, the quantity of infectious virus particles in 1 ml of virus stock, 
is critical for calculation of MOI in further experiments. In this work virus titres were 
determined by plaque assay for influenza. For this, 10-fold serial dilutions of virus 
stocks in VGM were prepared. To ensure accuracy of dilutions, tips were changed 
between every dilution.  
MDCK cells grown in 6-well plates were used for plaque assay. Cells were washed with 
PBS and 200 µl of virus dilutions were added to the wells. For control, one well was left 
non-infected and one well was infected with a virus of known titre. The infected cells 
were incubated for 1 hour with tilting every 15 minutes to prevent cells from drying 
and ensure even virus spread. After a 1 hour incubation cells were overlaid with 
minimal essential medium (MEM, Gibco) supplied with 1,2% Avicel (FMC BioPolymer), 
2mM L-Glutamine, 50 U/ml PenStrep, 0,2% BSA, and 1 µg/ml TPCK-trypsin to restrict 
the spread of new viruses to neighbouring cells (Image 1A).  
After 2 days of incubation, cells were fixed by adding 4 ml of fresh 4% formaldehyde in 
PBS. After 3 hours of incubation at room temperature the fixative was taken away, the 
cells were washed twice with PBS and 1 ml of staining solution (20% ethanol (Altia 
Oy), 3.6% formaldehyde, 1% methanol (Sigma-Aldrich), 0.1% crystal violet (Sigma 
Aldrich)) was added to each well. After 5 min incubation with staining solution cells 
were washed with tap water. In plaque assay each infectious particle produces a 
circular zone of infection, which results in cell death (Image 1B).  
A      B 
      
Image 1. A: Overlaid cells, B: Plaques  
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These infection zones are visualized as plaques – unstained circular zones in cell 
monolayer where the cells have been killed by viral infection. The plaques were 
calculated and a virus titre was determined as in formula 1: 
 
[1] Virus titre (pfu/ml) = [number of plaques] x [dilution coefficient] x 5 
 
4.2.5 Virus growth curves 
 
To obtain virus growth curves titres of viruses produced during a multiple cycle 
infection of MDCK cells with wt A/WSN/33 and its mutants were calculated. For this, 
MDCK cells were infected with IAVs at a MOI = 0,001 for a multiple cycle infection and 
supernatants containing new progeny viruses were collected at 12, 24, 36, 48 and 60 
hours post infection. The supernatants were clarified from dead cells and cell debris by 
centrifugation at 1200x g for 5 minutes and stored at -80 °C. The virus titres in 
supernatants were determined by plaque assays.   
 
4.3 Gene expression profiling  
In the field of molecular biology, gene expression profiling is the measurement of the 
activity of thousands of genes at once in order to create an overall picture of cellular 
function. These profiles show, for example, how the cells react to a particular 
treatment.  
For gene expression profiling human macrophages were infected with wild type and 
mutant A/WSN/33 viruses at MOI = 2. After 8 hours post infection total RNA was 
extracted from the cells using RNeasy Mini Kit (Qiagen) according to the 
manufacturer’s recommendations. The experiment was done in triplicates. Total RNA 
extracted from infected or non-infected macrophages was used to analyse gene 
expression using Illumina HT-12 v4 Expression BeadChip Kit according to the 
manufacturer’s instructions. Raw microarray data were quantile-normalized using the 
bioconductor R package Bead Array [40] and Limma [41]. The normalized data were 
further processed using a variance and intensity filter. Genes differentially expressed 
between different samples were determined using the limma R/Bioconductor package. 
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The Benjamini-Hochberg multiple testing correction method was used to filter out the 
differentially expressed genes on the basis of a q-value threshold (q<0.05). The 
resulting data were sorted by logarithmic fold change value (log2FC), genes with 
absolute log2FC>3 were selected for further analysis.  
4.4 Phosphokinase profiling 
For phosphokinase profiling human macrophages were infected with wild type wtWSN, 
WSN-202, WSN-210, WSN-220 at MOI = 2. Eight hours post infection the medium was 
removed and cells were frozen at -80 °C. Phosphokinase profiling was carried out using 
Human Phospho-Kinase Array (Proteome Profilertm Antibody Arrays, R&D Systems) 
according to the manufacturer’s instructions. Quantification of kinase production was 
done using ImageJ software. 
 
 
5 Results 
 
5.1 Characterization of viruses 
 
First we characterized the mutant viruses to be used in the experiments through 
growth-curve analysis. To address any possible effects of introduced NS1 truncations 
on virus replication, we studied virus propagation in MDCK cells. For this we infected 
the cells with a wild type WSN and mutants expressing truncated NS1 protein - WSN-
202, WSN-210 and WSN-220 with an MOI of 0,001. We then determined virus titres 
using plaque assays every 12, 24, 36, 48, 60 hours post infection. The data was 
reported as mean titres with standard deviations for three independent experiments as 
shown in Table 3 on the next page. 
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Table 3. The virus titration data  
12 24 36 48 60
 I II III I II III I II III I II III I II III
wt WSN 1,5E+05 1,0E+05 3,0E+05 6,5E+08 7,5E+08 7,0E+08 1,0E+09 2,0E+09 2,0E+09 4,0E+08 2,5E+08 3,5E+08 1,5E+08 1,3E+08 1,0E+08
202 1,0E+04 5,0E+03 5,0E+03 2,0E+07 4,5E+07 1,5E+07 3,0E+08 5,0E+08 4,0E+08 2,0E+08 3,5E+08 2,5E+08 3,0E+08 2,0E+08 1,0E+08
210 1,5E+04 1,0E+04 2,5E+04 7,5E+07 1,5E+08 9,5E+07 5,0E+08 1,5E+09 1,9E+09 3,5E+08 5,0E+08 1,0E+09 4,0E+08 1,0E+08 3,5E+08
220 5,0E+04 4,0E+04 2,5E+04 5,0E+08 7,0E+08 5,5E+08 2,0E+09 1,5E+09 2,0E+09 4,5E+08 1,0E+09 7,5E+08 4,0E+08 2,5E+08 3,5E+08
AVERAGE STDEV AVERAGE STDEV AVERAGE STDEV AVERAGE STDEV AVERAGE STDEV
wt WSN 1,8E+05 1,0E+05 7,0E+08 5E+07 1,7E+09 6E+08 3,3E+08 7,6E+07 1,3E+08 3E+07
202 6,7E+03 2,9E+03 2,7E+07 2E+07 4,0E+08 1E+08 2,7E+08 7,6E+07 2,0E+08 1E+08
210 1,7E+04 7,6E+03 1,1E+08 4E+07 1,3E+09 7E+08 6,2E+08 3,4E+08 2,8E+08 2E+08
220 3,8E+04 1,3E+04 5,8E+08 1E+08 1,8E+09 3E+08 7,3E+08 2,8E+08 3,3E+08 8E+07
 
 
At 24 hpi, when the wild-type virus had reached a titre of 7,0 x 108 pfu/ml, the titres of 
WSN-220, WSN-210 and WSN-202 were 1,2-fold, 6,3-fold and 25-fold lower, 
respectively. 
At 36 hpi, titres of wtWSN, WSN-220 and WSN-210 were almost the same while WSN-
202 lagged the first three ones by ~ 4-fold. At later stages of the observation period 
there were only minor differences between the viruses (Figure 15).  
 
 
 
Figure 15. Virus growth curves 
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We observed that the growth kinetics of WSN-220 strongly resembled those of the wild 
type as compared to WSN-202 and WSN-210 which showed a slight delay in growth 
and resulted in lower titres in the first half of the observation period. However, in the 
latter half they reached the titres of wtWSN and WSN-220, suggesting that the mutant 
viruses reach approximately the same titres as wtWSN but with a delay. Still, these 
results reveal that the NS1 protein with a 28-amino-acid-truncated C-terminus may 
impair viral infectivity to some extent. The analysis of the virus growth kinetics showed 
that wtWSN and all the created mutants had similar growth kinetics. The virus growth 
characteristics were mirrored in the phenotype of plaques in the plaque assay on 
MDCK cells where the mutants yielded well detectable plaques with the morphology 
similar to wtWSN (Image 2). 
wtWSN 10-7           WSN-202 10-6        WSN-210 10-6        WSN-220 10-7 
 
Image 2. Plaque assays 24 hpi.  
 
 
 
5.2 Gene expression profiling 
 
To observe whether or not the NS1 C-terminus affects cellular gene expression at 
transcriptional level we analysed expression of cellular genes in human macrophages 
infected with wtWSN, WSN-202, WSN-210 and WSN-220 viruses at 8 hours post 
infection. We found that the infection of macrophages with the wild type virus and the 
mutant viruses resulted in a strong (over 8-fold) overexpression of 74 cellular genes 
which are presented in a heat map (Figure 16). 
 
We compared the effects of different viruses on gene expression and observed that a 
virus with a 10-amino-acid truncation in NS1 (WSN-220) affected cellular gene 
expression quite similarly to that of wtWSN. The viruses with larger truncations had 
differential effects on gene expression. The truncation of 28 amino acids in NS1 (WSN-
202) resulted in stronger up-regulation of bigger number of genes which were 
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observed.  Remarkably, the deletion of 20 amino acids (WSN-210) prevented activation 
of the majority of cellular genes. The number of up-regulated genes by each of the 
examined viruses is shown in Table 4. 
 
 
Table 4. Summary of the number of up-regulated genes by each virus.   
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Figure 16. Heat map of log2-transformed fold change of gene expression level between       
virus-infected cells and mock (log2FC>3). 
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A heat map of gene expression values shows the effect of wild type and mutant virus 
infection on expression of cellular genes. The red colour indicates up-regulated 
expression.  
We observed that most of the affected genes were related to cellular antiviral 
responses and were involved in, e.g. signalling in the immune system, chemokine 
signalling, cytokine-cytokine receptor interaction, cytokine signalling and interferon 
signalling. 
Altogether, our results indicate that, compared to the wild type virus, a 10-amino-acid 
truncation in NS1 (WSN-220) does not have a noticeable effect on cellular gene 
expression. A truncation of 20 amino acids (WSN-210) allows the virus to suppress 
cellular gene expression more efficiently compared to wt. A 28-amino-acid truncation 
(WSN-202), in contrast, results in clearly reduced ability of the virus to inhibit cellular 
responses. On the basis of this finding it is plausible that some determinants in the C-
terminus amino acid stretch 202-210 make the virus more efficient in counteracting 
host responses whereas stretches 210-220 and 220-230 bring this enhanced ability 
back to a normal wild type virus level.       
5.3 Phosphokinase profiling 
To reveal the possible mechanisms by which the C-terminus of NS1 could affect cellular 
antiviral responses, we studied activation of phosphokinases in human macrophages 
infected with wtWSN, WSN-202, WSN-210 and WSN-220 or non-infected.  
 
Activation of phosphokinases by each virus was compared to uninfected cells. The 
value of each kinase in control (uninfected) cells was set to 1. Then the kinase 
activation levels in cells infected by wtWSN and the mutant viruses were normalized to 
mock-treated control cells. We observed that kinases HSP27, ERK1/2, JNK, Akt and c-
JUN as shown in Figure 17 on the next page were most activated in human 
macrophages infected with examined viruses.   
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Figure 17. Kinase activation 
Interestingly, whereas wtWSN, WSN-202 and WSN-220 did not have major differences 
in activation of kinases, WSN-210 resulted in increased phosphorylation of HSP27, 
ERK1/2, JNK, Akt and c-JUN. Since WSN-210 had also the strongest effect on 
transcription this result indicates that these effects may appear due to modulation of 
signaling pathways by a 210-amino-acid long NS1. 
All the examined viruses activated phosphorylation of kinases - except wtWSN in 
relation to ERK1/2. Phosphokinase profiling results showed that WSN-210 induces 
strongest activation what comes to all five kinases examined (Figure 14). The mutants 
WSN-202 and WSN-220 induced a similar level of kinase phosphorylation compared to 
each other. All the mutant viruses lead to increased phosphorylation of kinases 
compared to wtWSN with the exception of heat shock protein HSP27. 
HSP27 is a chaperone of the small heat shock protein group whose common functions 
are chaperone activity, thermotolerance, inhibition of apoptosis, regulation of cell 
development and cell differentiation [42]. The activation of HSP27 inhibiting cell 
apoptosis was significantly up-regulated by all the viruses. This extends viral replication 
which naturally assists virus propagation. Our data revealed that the WSN-210 with a 
20-amino-acid truncation in NS1 induces the strongest activity of this kinase indicating 
that it might be able to replicate longer than the other studied viruses and thus it is 
more efficient in infecting new cells.        
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ERK1/2 (the extracellular signal-regulated kinase) and JNK (the Jun-N-terminal kinase) 
belong to the mitogen-activated protein kinase (MAPK) family which is activated by 
virus infection in mammals. MAPK is responsible for important signaling pathways 
regulating cell activation, differentiation, apoptosis and immune responses. ERK1/2 due 
to its involvement in the transportation of viral NS2 protein and nucleoprotein (NP) and 
JNK have a key role in virus replication and proinflammatory responses in various 
human cells. [43.] 
ERK1/2 and JNK1/2 contribute strongly to the induction of IFN-β and subsequently to 
mRNA transcript levels of IFN-inducible antiviral proteins Mx which is responsible for a 
specific antiviral state against influenza virus infection and 2’-5’-oligoadenylate 
synthetase which is an antiviral enzyme counteracting viral attack by degrading viral 
RNA. [44.] The WSN-210 virus induces the strongest activity of these phosphokinases 
in macrophages indicating that it might encounter more difficulties in replicating in host 
cells than, for example, the wild type virus. However, this does not seem to affect the 
ability of WSN-210 to suppress the host cell antiviral gene expression and replicate 
successfully.       
Three closely related serine/threonine-protein kinases (Akt1, Akt2 and Akt3) are called 
the Akt kinase. Akt regulates many processes which are mediated through serine 
and/or threonine phosphorylation of a range of downstream substrates. Akt also 
influences cell survival via the phosphorylation of MAP3K5 (apoptosis signal-related 
kinase). Phosphorylation of 'Ser-83' decreases MAP3K5 kinase activity stimulated by 
oxidative stress and thereby prevents apoptosis. [44.] 
In several studies it was shown that the phosphatidylinositol-3-kinase (PI3K) and its 
downstream effector protein kinase Akt were induced upon IAV infection. The PI3K/Akt 
signaling is activated by various mechanisms and is required for various functions 
during viral infection. The early PI3K activity is required for efficient virus uptake and 
the later activation phase of PI3K prevents premature apoptosis. The virus-induced 
PI3K/Akt signaling pathway is an excellent example of a seemingly antiviral acting 
signaling pathway which is misused by the virus to ensure efficient replication and 
propagation. [45.] It appeared in our study that the Akt kinase was up-regulated in 
infected macrophages by 2- to 4-fold promoting efficient viral replication by supporting 
antiapoptotic signaling. 
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The c-Jun (transcription factor AP-1) kinase promotes activity of transcriptional 
activator NR5A1 (Nuclear receptor subfamily 5 group A member) [46]. Our results 
showed that this kinase activation was up-regulated 2- to 3-fold by all the viruses, 
WSN-210 again causing the highest activation level.   
6 Discussion 
 
Influenza A viruses have evolved various strategies to counteract multiple host antiviral 
defence mechanisms, often through the actions of the NS1 protein. In this study we 
wanted to find out the role that the NS1 C-terminus plays in the suppression of 
antiviral responses. 
The current study revealed that the wtWSN and all its mutations WSN-202, WSN-210 
and WSN-220 were able to suppress antiviral responses in host cells regardless of the 
length of NS1 C-terminus. Nevertheless, the virus with the shortest NS1 C-terminus 
seemed to bring out altogether more antiviral responses in infected cells than the other 
ones. The gene expression and kinase profiles of wtWSN and WSN-220 resembled 
each other much. The WSN-210 virus stood out from the rest clearly.  
The experiments showed that WSN-210 had the strongest influence on kinase activity 
as well as the most effective inhibition ability in regard to antiviral gene expression. 
Interestingly, these findings suggest that a WSN virus induces less antiviral responses 
and/or is able to suppress them best having a 20-amino-acid truncation in its NS1 C-
terminus in comparison with the other WSN mutations with a shorter or longer NS1 
protein and wtWSN.  
Based on this observation, we conclude that NS1 amino acids 211-230 may contain 
determinants affecting IAV capability to counteract host antiviral responses and, 
perhaps, pathogenicity compared to a 210-amino-acid long NS1. These may be sites 
targeted by host antiviral responses, for example. Again, it seems that a virus with too 
short a NS1 C-terminus (WSN-202) has also a weakened ability to respond to host 
defence mechanism. It might be worth studying further the amino acid stretch 202-
210.  
In summary, our data indicated that NS1 C-terminus may contribute to the suppression 
of cellular antiviral responses.  
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Ongoing molecular biology analyses deepen our understanding of virus-host 
interactions and support outbreak investigations of IAV. Understanding host responses 
and their underlying mechanisms may help us to find a way to take better control over 
IAV and to prevent future influenza pandemics. 
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